Banque de Luxembourg S.A. Invests $385,000 in ResMed Inc. (NYSE:RMD)

Banque de Luxembourg S.A. bought a new stake in ResMed Inc. (NYSE:RMD - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,677 shares of the medical equipment provider's stock, valued at approximately $385,000.

A number of other large investors have also recently bought and sold shares of RMD. World Investment Advisors LLC acquired a new position in ResMed during the third quarter worth $541,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of ResMed in the third quarter valued at about $193,000. Franklin Resources Inc. raised its holdings in ResMed by 56.5% during the third quarter. Franklin Resources Inc. now owns 174,113 shares of the medical equipment provider's stock worth $41,909,000 after acquiring an additional 62,882 shares in the last quarter. Principal Financial Group Inc. boosted its position in ResMed by 2.9% during the third quarter. Principal Financial Group Inc. now owns 186,776 shares of the medical equipment provider's stock valued at $45,596,000 after purchasing an additional 5,284 shares during the last quarter. Finally, Versant Capital Management Inc grew its stake in ResMed by 66.3% in the fourth quarter. Versant Capital Management Inc now owns 459 shares of the medical equipment provider's stock valued at $105,000 after purchasing an additional 183 shares in the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

Insiders Place Their Bets

In related news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total transaction of $484,220.00. Following the sale, the director now owns 77,218 shares in the company, valued at approximately $18,695,249.98. This trade represents a 2.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kaushik Ghoshal sold 9,113 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $235.40, for a total transaction of $2,145,200.20. Following the transaction, the insider now owns 9,725 shares of the company's stock, valued at approximately $2,289,265. This represents a 48.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 48,949 shares of company stock worth $11,283,302 in the last 90 days. Company insiders own 0.71% of the company's stock.

ResMed Stock Performance

Shares of ResMed stock traded up $1.52 during trading on Tuesday, reaching $242.18. The company's stock had a trading volume of 898,564 shares, compared to its average volume of 1,006,885. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The business's 50-day moving average price is $222.67 and its 200-day moving average price is $233.97. ResMed Inc. has a 52 week low of $179.42 and a 52 week high of $263.05. The firm has a market cap of $35.51 billion, a PE ratio of 28.59, a P/E/G ratio of 1.53 and a beta of 0.78.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.36 by $0.01. ResMed had a net margin of 25.34% and a return on equity of 26.17%. The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter in the previous year, the firm posted $2.13 EPS. The business's revenue for the quarter was up 7.9% compared to the same quarter last year. Equities analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Thursday, May 8th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 0.88%. The ex-dividend date is Thursday, May 8th. ResMed's dividend payout ratio (DPR) is currently 23.79%.

Analysts Set New Price Targets

RMD has been the subject of several recent analyst reports. KeyCorp set a $274.00 price objective on ResMed in a report on Thursday, April 24th. Mizuho set a $265.00 price objective on shares of ResMed in a research note on Wednesday, April 16th. StockNews.com upgraded ResMed from a "hold" rating to a "buy" rating in a report on Friday. Needham & Company LLC restated a "hold" rating on shares of ResMed in a research note on Friday, January 31st. Finally, UBS Group decreased their target price on ResMed from $290.00 to $285.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $258.83.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.